4//SEC Filing
Sabag Mark 4
Accession 0000950170-25-034617
CIK 0000818686other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:08 PM ET
Size
14.7 KB
Accession
0000950170-25-034617
Insider Transaction Report
Form 4
Sabag Mark
See "Remarks"
Transactions
- Exercise/Conversion
Ordinary Shares
2025-03-04+33,512→ 263,376 total - Exercise/Conversion
Ordinary Shares
2025-03-04+18,601→ 281,977 total - Exercise/Conversion
Ordinary Shares
2025-03-04+183,169→ 465,146 total - Exercise/Conversion
Restricted Share Units
2025-03-04−33,512→ 33,512 total→ Ordinary Shares (33,512 underlying) - Exercise/Conversion
Restricted Share Units
2025-03-04−18,601→ 55,803 total→ Ordinary Shares (18,601 underlying) - Exercise/Conversion
Restricted Share Units
2025-03-04−183,169→ 0 total→ Ordinary Shares (183,169 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.
- [F4]Restricted share units were granted on March 4, 2024, with 18,601 vested on March 4, 2025, and 18,601 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028.
- [F5]Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001721442
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:08 PM ET
- Size
- 14.7 KB